A Randomized, Double-blind, Placebo-controlled, Phase 1 Study of AER-01 (Solution for Inhalation, Delivered Via Nebulizer): As a First-In-Human Single Ascending Dose in Healthy Volunteers (Part A), and a 7-day Multiple Ascending Dose in Healthy Volunteers(Part B)
Latest Information Update: 13 Jan 2025
At a glance
- Drugs AER-01 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; First in man
- Sponsors Aer Therapeutics
Most Recent Events
- 08 Jan 2025 Results (N=96) presented in an Aer Therapeutics media release.
- 11 Jun 2024 Planned End Date changed from 1 Jul 2024 to 1 Aug 2024.
- 11 Jun 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Aug 2024.